SECsense Logo

Karyopharm Therapeutics Inc. 8-K Report: Key Corporate Updates & Stock Insights

$KPTI
Form 8-K
Filed on: 2025-02-19
Source
Karyopharm Therapeutics Inc. 8-K Report: Key Corporate Updates & Stock Insights

Based on the provided financial report section, here are the key points extracted:

  1. Entity Information:
  • Company Name: Karyopharm Therapeutics Inc.
  • CIK Number: 0001503802
  • SEC File Number: 001-36167
  • EIN: 26-3931704
  • Address: 85 Wells Avenue, 2nd Floor, Newton, MA 02459
  • Phone Number: (617) 658-0600
  1. Filing Type:
  • Form Type: 8-K (a report of unscheduled material events or corporate changes)
  1. Reporting Period:
  • Start Date: February 19, 2025
  • End Date: February 19, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.0001
  • Ticker Symbol: KPTI
  • Exchange: NASDAQ
  1. Additional Context:
  • The document is an XBRL filing, indicating it is structured for electronic data interchange with the SEC.

Insights:

  • The 8-K filing typically contains current information that may be important for investors, such as significant events affecting the company.
  • The timing of the report suggests that it pertains to a specific event occurring on the same date as the report, which could indicate a corporate event like earnings announcements, changes in executive management, or other significant news.
  • The company is listed on NASDAQ under the ticker KPTI, which may be relevant for investors looking to track its stock performance.

Overall, the document is crucial for investors and analysts monitoring Karyopharm Therapeutics Inc.'s corporate developments and stock performance.